7 Rare Disease FDA Decisions Fall in the Last 9 Days of November

In 2018, a woman named Marge started training for the Arkansas Women Can Run 5K in Little Rock. On her first training walk she was gasping for breath after a short distance. A kidney biopsy came back as membranous nephropathy, an autoimmune disease in which the body attacks the kidney's filters, and her kidney function was down to stage 4. Her doctor prescribed 3 infusions of rituximab, an immune drug used for the disease even though its FDA label does not mention it. After 2 infusions she was getting stronger. Then she retired, moved onto Medicare, and the third infusion never happened.

“I was unable to get the third ritux infusion. I was now retired and on Medicare ... Medicare would not cover ritux because it's off label for MN.”

Marge, at a patient-focused drug development meeting on membranous nephropathy attended by FDA officials, August 27, 2021

Marge ended her testimony with a question the FDA has not been able to answer for her disease in the 5 years since: "How will I treat it if rituximab is not an option?" Before the end of November, the FDA is due to decide whether membranous nephropathy gets its first approved drug. It is 1 of 11 rare disease decisions on the November calendar, and nearly all of them come back to the same thing Marge ran into, which is the label. The label is the FDA's list of who a drug is approved for. Insurers read it, doctors prescribe by it, and for a disease with nothing on its list, a family is left to argue.

Off-Label Rituximab and Why the FDA Label Decides Who Gets a Rare Disease Drug

Off-label means a doctor is using an approved drug for something its label does not cover. It is legal and, in rare disease, routine, because most rare diseases have no approved drug at all. What off-label cannot do is guarantee payment. Whether a plan covers an off-label use depends on the plan and the evidence, and in Marge's case Medicare said no to a drug that, by her account, was working.

Keep Marge in mind as you read the rest of this, because she is not the only one in this story fighting a label. The families waiting on November's decisions have each found their own workaround: a lung wash under general anesthesia, a cancer drug borrowed for a kidney disease, a spinal infusion given through a compassionate use program. A decision day is the day a workaround can become a prescription.

The month starts quietly and ends in a pile. Mitapivat's goal date for sickle cell disease falls on Sunday, November 1st. Adrabetadex for Niemann-Pick disease type C follows on November 17th. Then, starting Sunday, November 22nd, 7 decisions land in 9 days: 2 on that Sunday, 1 the day before Thanksgiving, 2 on the Friday after it, and 2 more on Monday, November 30th. Gazyva and cemdisiran are also due in November, on days their makers have not disclosed.

That calendar has 2 quirks that matter for families. A goal date is a deadline, not an appointment, and the FDA can act before it: in September, 6 of 8 rare disease decisions came early, 2 of them by 19 days (September roundup). The second quirk is the 3-month extension. When a company sends the FDA a large batch of new data in the middle of a review, the agency can call it a major amendment and push its own deadline back 3 months. That happened to adrabetadex, Molbreevi and deramiocel this year (Beren, 2026; Savara, 2026; Capricor, 2026).

Gazyva, Molbreevi, BBP-418 and Venglustat Could Be First FDA-Approved Drugs

November has 4 decisions for diseases, or forms of a disease, with nothing on the FDA's list today. For each one, families have been living on a workaround, and every one of these drugs took a detour on the way here.

Gazyva for Primary Membranous Nephropathy, Decision Due by the End of November

Marge's disease is the clearest case. Genentech says there is no FDA- or EMA-approved therapy for primary membranous nephropathy, a disease diagnosed in about 1.2 of every 100,000 Americans a year, and that up to 30% of patients reach kidney failure within 10 years (Genentech, 2026). Doctors use rituximab, cyclophosphamide, tacrolimus and cyclosporine, all off label. The FDA granted Gazyva (obinutuzumab) Breakthrough Therapy designation for the disease in April 2026 and priority review in July, with a decision expected by November (Genentech, 2026). Genentech has not disclosed the exact day.

Gazyva removes B cells, the immune cells that make the antibodies attacking the kidney, as rituximab does, but it is engineered to kill them more directly. In the MAJESTY trial (NCT04629248), 142 adults got either 4 Gazyva infusions over 26 weeks or tacrolimus, a standard pill. At 2 years, 37% on Gazyva were in complete remission, meaning the protein leak had essentially stopped, against 6% on tacrolimus (Fervenza et al., NEJM, 2026). That number comes with 2 caveats. The trial was open label, so everyone knew what they were taking, and a key secondary goal, slowing the loss of kidney function, was not met. Rates of serious side effects were similar, 17% against 14%.

Gazyva's detour is that it began as a drug for chronic lymphocytic leukemia, a blood cancer. It added lupus nephritis in October 2025 and idiopathic nephrotic syndrome in September 2026 (Genentech, 2025 and 2026). If it adds membranous nephropathy, a cancer drug will have picked up 3 kidney diseases in about 13 months. The trial enrolled adults only, so children with the disease would remain off label.

Molbreevi for Autoimmune Pulmonary Alveolar Proteinosis, November 22nd

In autoimmune pulmonary alveolar proteinosis (aPAP), the body makes antibodies against GM-CSF, a signal the lungs' cleanup cells need to clear away used surfactant, the slippery film that keeps air sacs open. The surfactant piles up until breathing fails. The standard fix is whole lung lavage: under general anesthesia, one lung is filled with salt water and drained, again and again, while the other lung breathes. There is no FDA-approved drug (Savara, 2026).

“I felt trapped in my own body.”

Karli, an aPAP patient, at the FDA patient-focused drug development meeting, May 7, 2025 (Voice of the Patient report, NORD and the PAP Foundation, 2026)

Karli told the meeting that she could not get lavage as often as she needed because it was "too resource intensive to have 4 anesthesiologists in the operating room" (Voice of the Patient report, 2026). Her workaround, like that of many patients in the report, is sargramostim, a GM-CSF drug approved for other uses and given off label, often after a fight with an insurer. Molbreevi (molgramostim) is an inhaled GM-CSF made for aPAP, breathed in once a day through a small nebulizer.

In the IMPALA-2 trial (NCT04544293), 164 adults with aPAP got Molbreevi or placebo for 48 weeks. The main measure was DLCO, a breathing test of how well oxygen passes from the lungs into the blood. At week 24 it rose 9.8 points of predicted on Molbreevi against 3.8 on placebo, and quality-of-life scores improved more as well, though an activity score did not (Trapnell et al., NEJM, 2025). Serious side effects were less common on the drug than on placebo, 17% against 24% (ClinicalTrials.gov, 2026).

Molbreevi's detour runs through 2 setbacks. Its first Phase 3 trial, IMPALA, missed its main goal in 2019, and the measure that worked there, DLCO, became the main goal of the second trial (Savara, 2019). Savara's first application, in 2025, was refused before review because the manufacturing section was incomplete (Fierce Pharma, 2025). The FDA accepted the resubmission with priority review in February 2026, said no advisory committee is planned, and then pushed the goal date from August 22nd to November 22nd after Savara answered its questions (Savara, 2026; BioPharm International, 2026). The extension notice said the FDA had not raised safety, efficacy or manufacturing concerns.

BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9, November 27th

Limb-girdle muscular dystrophy type 2I, also called LGMDR9, weakens the hips and shoulders first and often the heart and breathing muscles later. It comes from mutations in the FKRP gene, which helps put sugar chains on alpha-dystroglycan, a protein that anchors muscle fibers. There is no FDA-approved treatment for any form of limb-girdle muscular dystrophy (VCU Health, 2026). BBP-418 is an oral form of ribitol, a sugar the body makes, given in large amounts so that the partly working FKRP enzyme has more raw material to finish its job (BridgeBio, 2026).

Kelly Brazzo's daughter Sammy was diagnosed at age 2. In November 2025, when Sammy was 17, Kelly wrote that her daughter was "working hard to be able to walk across the stage" at her high school graduation, and that she and her husband had learned early that "we'd have to help make it happen ourselves" (PennLive, 2025). They founded what is now CureLGMD2i in 2011. Her essay was a plea to Congress to renew the rare pediatric disease priority review voucher program, which pays companies that win approval for a children's rare disease with a voucher to speed up a later review. Hold on to that voucher; it comes back later in this story.

The pivotal FORTIFY trial (NCT05775848) enrolled 112 people aged 12 to 60. At a planned 12-month interim look, the sugar-coated form of alpha-dystroglycan rose 1.8 times from baseline, CK, a blood sign of muscle damage, fell 82%, and treated patients walked a timed 100 meters 0.27 meters per second faster than the placebo group (BridgeBio, 2025). Diarrhea, the most common side effect, was actually less frequent on the drug than on placebo, 39% against 53% (BridgeBio, 2026). The company is asking for traditional approval rather than accelerated approval, and the FDA is not planning an advisory committee. The trial's final goal, a motor score at 36 months, has not been reported yet.

BBP-418's detour started with 2 families. In 2001 the McColl and Lockwood families in Charlotte, one of them with a child diagnosed with LGMD2I, began funding a lab at what is now Atrium Health, where the scientist Qi Long Lu worked out the ribitol idea; the program was spun out in 2018 and bought by BridgeBio in 2019 (Global Genes; Atrium Health, 2021). "Living with LGMD2I/R9 is a daily negotiation with limits," said Dan Pope, who lives with the disease and is vice president of CureLGMD2i (BridgeBio, 2025).

Venglustat for Gaucher Disease Type 3, November 25th

Gaucher disease has several approved drugs, but none reaches the brain. In type 3, the form with neurological symptoms, a fatty substance builds up in the nervous system as well as the spleen, liver and bone marrow, causing loss of balance and coordination and problems with thinking. Enzyme replacement infusions treat the body but cannot cross into the brain, and the only label that mentions type 3, Cerezyme's, covers its non-neurological symptoms (Cerezyme label, 2026). Venglustat is a once-daily pill designed to cross into the brain and slow the making of the fatty substance at its source (Sanofi, 2026).

In LEAP2MONO (NCT05222906), 43 people aged 12 and older who had been on enzyme infusions for at least 3 years were switched either to venglustat or kept on infusions, with dummy pills and dummy infusions so nobody knew which. After a year, a combined score of balance and thinking favored venglustat (p=0.0179), and spleen size, liver size and hemoglobin held up as well as on infusions (Sanofi, 2026). The trial was small, and Sanofi has not published the size of the effect on each scale. Headache, nausea, diarrhea and an enlarged spleen were each reported in 14% of venglustat patients. If approved, Sanofi says it would be the first US treatment for the neurological symptoms of type 3.

Jo Bardoe's daughter Mia was diagnosed with type 3 just after her first birthday in December 2000 and later spent 3 years in a trial of miglustat, an earlier pill that also crosses into the brain, "which sadly did not work" (Gauchers Association, UK). That 2008 trial is part of venglustat's detour, and Sanofi's own record is the rest: venglustat was stopped in a kidney disease in 2021, failed in a Parkinson's trial, was dropped in GM2 gangliosidosis, and missed its main goal in Fabry disease in February 2026 (Sanofi, 2021; Fierce Biotech, 2026). Gaucher type 3 is the one place it has won.

Adrabetadex for Niemann-Pick Type C and Deramiocel for Duchenne, the Comeback Decisions

November also has 2 drugs under review after setbacks that would have ended most programs, and both are in children's diseases where parents built the evidence themselves.

Adrabetadex for Infantile-Onset Niemann-Pick Disease Type C, November 17th

Niemann-Pick type C traps cholesterol inside cells and slowly destroys the brain. The FDA has approved 2 drugs, Miplyffa for ages 2 and up together with miglustat and Aqneursa for patients who weigh at least 15 kg, but neither targets the trapped cholesterol directly (FDA, 2024; Aqneursa label, 2026). Adrabetadex is a cyclodextrin, a ring-shaped sugar that pulls cholesterol free, infused into the spinal fluid every 2 weeks. Beren Therapeutics is seeking approval for the infantile-onset form, children whose neurological symptoms start before age 6 (Beren, 2026).

The drug's detour may be the longest in this batch. In 2009 the FDA allowed cyclodextrin for twin girls in Reno, Addi and Cassi Hempel, under compassionate use at their parents' urging; the twins died in July 2019 (Global Genes, 2019). A randomized trial, VTS301, failed in 2018, its sponsor Mallinckrodt went bankrupt and ended the program in 2020, and Beren took it over in 2021 (Beren, 2026; BioPharma Dive, 2018). The FDA even rescinded the drug's Breakthrough Therapy designation and then granted it again in December 2025.

The case for approval now rests on survival. In 72 treated children compared with 119 similar children from outside records, adrabetadex was linked to a 71% lower risk of death, and 5-year survival was 84% against 42% (Beren, 2026). That kind of external comparison is weaker than a randomized trial, because treated children and record-based children can differ in ways that have nothing to do with the drug. Hearing loss was seen in every participant of an early trial and remains the main known side effect (Ory et al., Lancet, 2017). The goal date moved from August 17th to November 17th after a major amendment.

Deramiocel for Duchenne Muscular Dystrophy, November 22nd

Deramiocel is a cell therapy made from donated heart cells and given by vein every 3 months. In 2011 Catherine Jayasuriya, whose son Dusty was diagnosed with Duchenne muscular dystrophy at 6, read about the cardiologist Eduardo Marbán's heart cell research and persuaded him to try it in Duchenne; she later raised $150,000 to fund the early work (Cedars-Sinai, 2025). "There may be something that works for another condition," she said.

Its regulatory path has been a roller coaster. The FDA rejected the first application in July 2025. In the HOPE-3 trial (NCT05126758), 106 boys and young men, most of them no longer able to walk, got deramiocel or placebo, and Capricor's analysis showed upper limb function declining 54% more slowly, published in The Lancet (McDonald et al., Lancet, 2026). The FDA's analysis under the trial's original plan did not reach significance, and in July 2026 an advisory committee voted 9 to 3 that the evidence did not show the drug works for Duchenne heart disease, the use Capricor had applied for (FDA, 2026; Capricor, 2026). Capricor then sent 2 years of follow-up data and asked the FDA to consider an upper limb indication instead, which moved the goal date to November 22nd. Our Duchenne exon skipping guide covers the other Duchenne drugs under review.

New Options for PBC, GIST, IgA Nephropathy, Sickle Cell Disease and Myasthenia Gravis

The other 5 decisions are for diseases that already have approved drugs. For these families the question is not whether something exists but whether something better does.

Saroglitazar for Primary Biliary Cholangitis, November 27th

In primary biliary cholangitis (PBC) the immune system destroys the liver's small bile ducts. Ursodiol comes first, and 2 newer pills, Iqirvo and Livdelzi, are approved for people who do not respond well enough to it. A third second-line option, Ocaliva, was withdrawn in November 2025 (Federal Register, 2025). Saroglitazar, a once-daily pill that works on 2 related receptors that control bile acids and inflammation, would be the third pill in that group (Zydus, 2026).

In the Phase 3 part of EPICS-III (NCT05133336), 148 patients were randomized, and 56.7% on saroglitazar reached the trial's definition of a lab response at 1 year against 9.8% on placebo. Only 8.2% got liver enzyme levels all the way back to normal, and the itch relief seen at 6 months had faded by 1 year (Zydus, 2026). The results have not yet been published in a journal. Zydus plans a US launch by March 2027 if approved.

Itch is what patients describe first. "It's not an itch that you can scratch off," said Hilary Paradise, who leads a PBC support group in Hendersonville, North Carolina (FOX Carolina, 2026). Saroglitazar's detour is geographic: it has been sold in India since 2013 as Lipaglyn, a pill for diabetic cholesterol problems, and is now being tried in a rare American liver disease (Agrawal, 2014).

Bezuclastinib Plus Sunitinib for GIST, November 30th

Gastrointestinal stromal tumor (GIST) is a rare cancer of the digestive tract, with about 6,000 US cases a year (American Cancer Society). Most are driven by a mutated KIT gene and respond first to imatinib, but the tumor eventually mutates around it. Since 2006 the next step has been sunitinib alone. Lee Keenan, a triathlete diagnosed at 42, has been through imatinib, sunitinib and 3 later drugs and put it simply.

“The last three didn't even exist at that time.”

Lee Keenan, on the GIST drugs he has taken since his 2011 diagnosis (CURE)

Cogent Biosciences wants to add bezuclastinib, a pill that blocks the KIT mutations sunitinib misses, to sunitinib in the second-line slot. In the PEAK trial (NCT05208047), 413 patients got the combination or sunitinib alone, and the median time before the cancer grew was 16.5 months against 9.2 months (Cogent, 2026). The trial was open label and survival data are not mature yet. Liver enzyme rises were much more common with the combination, 56% against 17% at any grade. Cogent calls it the first positive Phase 3 trial in second-line GIST in more than 20 years. Its detour: the drug came to Cogent in 2020 when Unum Therapeutics, a struggling cell therapy company, acquired the license and remade itself (Cogent, 2020).

Povetacicept for IgA Nephropathy, Mitapivat for Sickle Cell and Cemdisiran for Myasthenia Gravis

We have covered these 3 in depth already, so here is what has changed. Povetacicept for IgA nephropathy has a November 30th goal date under an accelerated approval request, and Vertex used a priority review voucher to speed its review (Vertex, 2026). It would be the second drug that blocks both BAFF and APRIL, after Trutakna, which our atacicept vs povetacicept comparison covers in detail. It would also arrive after Fabhalta converted to full approval on July 16, 2026 for slowing the loss of kidney function (Drugs@FDA).

Mitapivat for sickle cell disease has a Sunday, November 1st goal date. Its trial raised hemoglobin in 40.6% of patients against 2.9% on placebo but did not significantly reduce pain crises, and our mitapivat decision guide walks through what that means (Agios, 2025). Cemdisiran, an siRNA from Regeneron injected every 12 weeks that turns down the liver's production of complement protein C5, is due in November for adults with AChR antibody-positive myasthenia gravis; in the NIMBLE trial it improved daily-living scores by 2.3 points more than placebo, and Regeneron also used a priority review voucher (Vu et al., Lancet, 2026; Regeneron, 2026). Our myasthenia gravis drug comparison lists the drugs it would join.

What Happens on an FDA Decision Day and How a Rare Disease Approval Can Still Stall

A decision day ends 1 of 3 ways, and this month has examples of all 3 already in its history.

The thing that turns a workaround into a prescription is the approval branch, and specifically the words on the label. An approval for adults does not cover children. An approval tied to an AChR antibody does not cover other antibody types. A label for the neurological symptoms of Gaucher type 3 says nothing about type 1. When a decision comes in, the first thing to read is the indication, the 1 or 2 sentences at the top of the label that say who it is for.

Thanksgiving Week, Priority Review Vouchers and the Rare Disease FDA Pileup

Why do so many decisions land in the same week? Partly by accident: 3 deadlines were each pushed back exactly 3 months, and 2 of the new dates collided on the Sunday before Thanksgiving. Partly by design. Priority review sets the FDA's goal about 6 months after it formally files an application, so applications filed in late spring line up in late fall. Vertex and Regeneron bought their way onto that faster clock with priority review vouchers, for povetacicept and cemdisiran (Vertex, 2026; Regeneron, 2026).

This is where Kelly Brazzo comes back. The voucher she asked Congress to save rewards companies for approvals in rare children's diseases, and Congress revived the program on February 3, 2026, through September 2029 (Fierce Pharma, 2026). Adrabetadex and deramiocel both hold the Rare Pediatric Disease designation that can earn one (Beren, 2026; Capricor, 2026). An approval in a children's disease this November can come with one.

Put the 3 threads side by side and they turn out to be the same story. Marge, Karli and Kelly Brazzo each ran into a wall that was really a missing label: a drug that worked but was not written for her disease, a lung wash that needed 4 anesthesiologists she could not always get, a disease with nothing approved at all. The detours, the failed trials and rescued programs and cancer drugs repurposed for kidneys, are how drugs for small diseases get to the FDA at all. The clock, with its extensions and vouchers and Sunday deadlines, decides when the wall comes down. For Marge's disease and 3 others, an answer could arrive in the same 30 days.

None of these approvals is guaranteed, and any of them could slip again. What you can do does not depend on the outcome. Sign up for the alert on the decision page for your disease, so you hear the day it happens. Ask your specialist now, before the decision, whether you match the trial population. When a label comes out, read the indication at the top and ask your insurer whether they will cover it for your diagnosis. If you are in a situation like Marge's, an on-label option is a new argument to make.

November 2026 FDA Decisions: Frequently Asked Questions